Introduction
In a major biomedical breakthrough for diabetes management, scientists at the Council of Scientific and Industrial Research–Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad, announced on 16 August 2026 the development of a standardized, plant-based Investigational New Drug (IND)-ready candidate derived from Gymnema sylvestre (commonly known as Gurmar or Sirukurinjan) for treating chronic diabetic foot ulcers (DFUs).
Therapeutic Mechanism & Phytochemical Profile
Diabetic foot ulcers represent severe microvascular complications characterized by impaired wound healing, peripheral neuropathy, and secondary bacterial infections, frequently leading to lower-limb amputations:
- Bioactive Triterpenoid Saponins: The formulation isolates enriched gymnemic acids and triterpenoid glycosides that accelerate fibroblast proliferation, promote collagen deposition, and stimulate angiogenesis in hypoxic ulcer tissues.
- Potent Antimicrobial & Anti-inflammatory Action: Demonstrates broad-spectrum bactericidal efficacy against multi-drug resistant (MDR) pathogen bio-films, including Staphylococcus aureus and Pseudomonas aeruginosa.
- Pre-Clinical Safety: Pre-clinical pharmacokinetic and toxicological evaluations confirmed high dermal safety, rapid epithelial re-surfacing, and zero systemic toxicity.
Key Facts
- Scientific Discovery: Plant-based IND-ready formulation for Diabetic Foot Ulcers
- Developing Institution: CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad
- Botanical Source: Gymnema sylvestre (Family: Apocynaceae / Tamil: சிறுகுறிஞ்சான் / Hindi: गुड़मार)
- Primary Clinical Target: Accelerating wound healing and preventing amputations in diabetic patients
- Regulatory Stage: Investigational New Drug (IND) ready for human clinical trials
Exam Perspective
For TNPSC and UPSC examinations, this topic covers Science & Technology, Biotechnology & Phytomedicine, CSIR Research Innovations, Diabetes Complications, and Medicinal Plants of India in GS Paper III.
Conclusion
The CSIR-IICT breakthrough highlights the vast potential of Indian traditional phytomedicine in addressing critical unmet clinical needs in chronic metabolic disease management.